Duration of Treatment With Tyrosine Kinase Inhibitors in the Treatment of Metastatic Renal Cell Carcinoma

Duration of Treatment With TKIs in the Treatment of Metastatic Renal Cell Carcinoma

This study is a prospective, non-interventional, non-controlled, multi-center, observational cohort study. The medication is prescribed within the regular practice of the physician. Duration and dosage of treatment is solely at the discretion of the attending physician. The primary objective of this study is to assess duration of treatment in Turkish renal cell carcinoma patients treated with TKIs (Tyrosine Kinase Inhibitors) who could not tolerate prior cytokine treatment within the first month of treatment.

Inclusion Criteria:

• To be diagnosed as metastatic renal cell carcinoma
• Previous cytokine therapy
• To sign informed consent form (ICF)

Exclusion Criteria:

• Patients not willing to sign informed consent form or who withdraw their consent